<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04440085</url>
  </required_header>
  <id_info>
    <org_study_id>RaGuS</org_study_id>
    <nct_id>NCT04440085</nct_id>
  </id_info>
  <brief_title>RaGuS Trial by Postoperative Patients</brief_title>
  <acronym>RaGuS</acronym>
  <official_title>RANDOMIZED CASE-CONTROLLED TRIAL ASSESSING MIDODRINE (GUTRON®) IN POSTOPERATIVE VASOPLEGIC PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bürgerspital Solothurn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bürgerspital Solothurn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoplegic syndrome is characterized clinically by reduced systemic vascular resistance and
      normal or increased cardiac output. It is principally observed in cardiovascular and
      orthopedic interventions and is characterized by a systemic inflammatory response with the
      inability of the vascular endothelial muscles to contract and a resistance to the action of
      vasoactive drugs. This event extends the length of stay in the critical care area due to the
      need of vasoactive drugs.

      The investigators aim to assess the standardized application of midodrine in postoperative
      patients without sepsis and need of vasoactive drugs in order to reduce the length of stay in
      critical care area and for extension in hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Midodrine is an alpha 1 receptor agonist used usually in cases of hypotension helping to
      increase blood pressure. The main indication is orthostatic hypotension but there are other
      clinical conditions where this medicament is often used like hypotension by dialysis,
      hepatorenal syndrome and after carotid artery stenting.

      Vasoplegic syndrome coul be interpreted as a variant of orthostatic hypotension that happens
      usually after surgical interventions. It produces a loss of systemic vascular resistance due
      to inflammatory reaction without any signs of infection.

      The investigators aim to conduct a randomized, double-blind, single-center,
      placebo-controlled study of midodrine in patients who present postoperative vasoplegia with
      no active signs of sepsis but need of vasoactive drugs (Noradrenalin).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">September 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, single-center, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time</measure>
    <time_frame>aproximately 2 days</time_frame>
    <description>Hours from initiation of treatment with midodrine to discharge from critical care area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>aproximately 7 days</time_frame>
    <description>days in critical care area and hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopresors</measure>
    <time_frame>aproximately 2 days</time_frame>
    <description>Noradrenalin needed doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>aproximately 2 days</time_frame>
    <description>cumulative fluid balance in mililiter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vasoplegic Syndrome</condition>
  <condition>Sirs Due to Noninfectious Process Without Organ Dysfunction</condition>
  <condition>Orthostatic Hypotension</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midodrine will be administered every 8 hours, increasing the dose gradually until a maximum of 30 mg a day is reached. It will be given orally in the following sequence: 2.5 mg - 5 mg - 7.5 mg - 10 mg. The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) &gt; 65 mmHg, with unchanged dose of midodrine after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>By placebo group will be followed the same strategy.The target standard perfusion pressure for all the patients will be a mean arterial pressure (MAP) &gt; 65 mmHg, with unchanged dose of placebo after target pressure is reached. If the pressure continues to increase, the same sequence will be followed for dose de-escalation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine Hydrochloride</intervention_name>
    <description>All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Midodrine will be administered according to the evolution of the patient's mean pressure.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>All patients become standard care resuscitation treatment using liquids and vasoactive drugs in order to get a median arterial pressure ≥ 65 mmHg. Placebo will be administered according to the evolution of the patient's mean pressure.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years of age

          -  Need of vasoactive drugs after three hours from arrival and adequate volume recovery.

        Exclusion Criteria:

          -  Signs of infection (anamnesis or pro-calcitonin &gt; 0.2 with leukocytosis, CRP and/or
             fever)

          -  Serum lactate &gt; 2mmol/l

          -  Mechanical ventilation

          -  Therapeutic restrictions or comfort measures at arrival

          -  &quot;de novo&quot; or acute on chronic heart failure (Reduction of known ejection fraction for
             more than 20 percent, signs of acute lung edema)

          -  Pregnant

          -  Patients with digoxin treatment or history of glaucoma.

          -  History of midodrine allergy, pheochromocytoma, thyrotoxicosis, tachyarrhythmias or
             ventricular fibrillation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos Delgado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bürgerspital Solothurn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcos Delgado, MD</last_name>
    <phone>+4132627</phone>
    <phone_ext>3820</phone_ext>
    <email>marcos.delgado@spital.so.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>René Fahrner, MD</last_name>
    <phone>+4132627</phone>
    <phone_ext>3398</phone_ext>
    <email>r.fahrner@web.de</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020 Jun;57:148-156. doi: 10.1016/j.jcrc.2020.02.011. Epub 2020 Feb 19. Review.</citation>
    <PMID>32145658</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaefi S, Mittel A, Klick J, Evans A, Ivascu NS, Gutsche J, Augoustides JGT. Vasoplegia After Cardiovascular Procedures-Pathophysiology and Targeted Therapy. J Cardiothorac Vasc Anesth. 2018 Apr;32(2):1013-1022. doi: 10.1053/j.jvca.2017.10.032. Epub 2017 Oct 27. Review.</citation>
    <PMID>29223724</PMID>
  </results_reference>
  <results_reference>
    <citation>Jans Ø, Mehlsen J, Kjærsgaard-Andersen P, Husted H, Solgaard S, Josiassen J, Lunn TH, Kehlet H. Oral Midodrine Hydrochloride for Prevention of Orthostatic Hypotension during Early Mobilization after Hip Arthroplasty: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2015 Dec;123(6):1292-300. doi: 10.1097/ALN.0000000000000890.</citation>
    <PMID>26492477</PMID>
  </results_reference>
  <results_reference>
    <citation>Smits M, Lin S, Rahme J, Bailey M, Bellomo R, Hardidge A. Blood Pressure and Early Mobilization After Total Hip and Knee Replacements: A Pilot Study on the Impact of Midodrine Hydrochloride. JB JS Open Access. 2019 May 14;4(2):e0048. doi: 10.2106/JBJS.OA.18.00048. eCollection 2019 Apr-Jun.</citation>
    <PMID>31334462</PMID>
  </results_reference>
  <results_reference>
    <citation>Levine AR, Meyer MJ, Bittner EA, Berg S, Kalman R, Stanislaus AB, Ryan C, Ball SA, Eikermann M. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013 Oct;28(5):756-62. doi: 10.1016/j.jcrc.2013.05.021. Epub 2013 Jul 8.</citation>
    <PMID>23845791</PMID>
  </results_reference>
  <results_reference>
    <citation>Cardenas-Garcia JL, Whitson MR, Healy K, Koenig S, Narasimhan M, Mayo P: Safety of oral midrodrine as a mehtod of weaning from intravenous vasoactive medication in the medical intensive care unit. Chest 2014, 146(4):224A.</citation>
  </results_reference>
  <results_reference>
    <citation>Rizvi MS, Nei AM, Gajic O, Mara KC, Barreto EF. Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. Crit Care Med. 2019 Aug;47(8):e648-e653. doi: 10.1097/CCM.0000000000003814.</citation>
    <PMID>31107279</PMID>
  </results_reference>
  <results_reference>
    <citation>Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4.</citation>
    <PMID>26953217</PMID>
  </results_reference>
  <results_reference>
    <citation>Anstey MH, Wibrow B, Thevathasan T, Roberts B, Chhangani K, Ng PY, Levine A, DiBiasio A, Sarge T, Eikermann M. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial). BMC Anesthesiol. 2017 Mar 21;17(1):47. doi: 10.1186/s12871-017-0339-x.</citation>
    <PMID>28327122</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 13, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bürgerspital Solothurn</investigator_affiliation>
    <investigator_full_name>Marcos Delgado</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Midodrine</keyword>
  <keyword>Vasoplegic syndrome</keyword>
  <keyword>Noradrenaline</keyword>
  <keyword>SIRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension, Orthostatic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have decided for the Trial not to share the participant Information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

